Drugs and patents in ATC class D07A - CORTICOSTEROIDS, PLAIN

Last updated: July 27, 2026

Executive summary

ATC D07A (plain corticosteroids) is a crowded, low-to-mid branded market where incremental patent layers (formulation, particle/crystallinity, device, method of use, and process) drive most lasting IP beyond primary API coverage.
Generic entry risk concentrates where (1) Orange Book coverage is thin for the marketed NDA/ANDA products, (2) formulation patents are narrow (e.g., single excipient system or single concentration), and (3) competition is already multi-product, multi-strength.
Patent estates typically peak in value for each brand’s specific strength and dosage form (cream, ointment, lotion, gel), not across the whole steroid class.
For new entrants and generic filers, the highest leverage is finding active formulation/process patents tied to the exact marketed presentation and filing strategy to avoid Paragraph IV exposure while using safe design-around targets.

What is ATC D07A (plain corticosteroids) and how is the market segmented?

ATC D07A covers topical corticosteroids used for inflammatory and pruritic dermatoses, excluding combination products that include additional actives (those map to other ATC dermatology subgroups). Market segmentation is largely by:

Molecule (API): medium/high potency steroids dominate reimbursement and physician familiarity in many geographies.
Dosage form: ointments and creams lead; lotions and gels capture scalp and hairline indications; foams are narrower but higher-growth in certain countries.
Potency band: low potency products face faster commoditization; mid and high potency face heavier IP survivorship due to formulation and device differentiation.
Strength/concentration: IP and regulatory coverage are presentation-specific (same molecule at a different concentration can have different listing and different patent terms).

Which corticosteroid APIs commonly sit in D07A?

The class is typically populated by well-known topical steroids such as:

Hydrocortisone and related low potency steroids
Betamethasone esters
Mometasone
Triamcinolone
Clobetasol derivatives
Fluocinolone acetonide
Desonide
Fluticasone
Alclometasone These APIs are sold across multiple presentations, and the patent landscape varies per molecule and presentation, not across the class.

Where does growth come from?

Switch from low potency OTC or generics to prescription mid/high potency for atopic dermatitis, eczema, and localized inflammatory disease.
Patient adherence improvements (vehicle feel, spreadability, fast drying) that can be patented at the formulation level.
Expanded labeling can drive shelf life and higher potency acceptance, but patent coverage still tracks to formulation and method-of-use claims.

How do patent dynamics work for topical steroids (D07A) compared with systemic drugs?

Topical steroid IP typically breaks into four layers:

Primary composition of matter: often expires earlier and covers the API family rather than the specific marketed formulation.
Formulation patents: thickening system, solvent/penetration enhancer choices, polymorph/crystal form, particle size, and stability constraints tied to one strength.
Manufacturing/process patents: granulation, milling, mixing, heating/cooling steps, and sterilization or aseptic steps where relevant.
Method-of-use patents: regimen, dosing frequency, vehicle choice for a specific disease area, pediatric-specific use, or regimen duration windows.

Typical survivorship pattern

If the original API patent is long expired, brands extend exclusivity through formulation and process that map to the exact dosage form and strength on the label.
Where multiple strengths exist, exclusivity can fragment, producing a situation where one strength faces early generic entry while another is still protected.

What patents protect plain topical corticosteroid products in practice (formulations, processes, and methods)?

For D07A, the most consequential patents in litigation or licensing are usually:

“Formulation to get penetration” patents: claims tied to a specific base, surfactant system, or vehicle that improves delivery and persistence.
“Particle engineering” patents: particle size distributions or crystallinity for poorly soluble steroids.
“Stability and viscosity” patents: shelf-life extension and controlled viscosity ranges that match the marketed product.
“Manufacturing” patents: specific blending/milling and cooling profiles that define the product’s critical quality attributes.

Method-of-use patents: what do they usually claim?

Method claims tend to be narrower than users expect:

disease-specific regimens (e.g., eczema flares)
dosing frequency limits
tapering protocols
site-specific use that relies on penetration physics and patient compliance

These can be strong in enforcement but are harder to use to block manufacturing-based generic products unless the jurisdiction and claims are drafted to capture therapeutic effect or administration.

When does exclusivity end for D07A topical steroids? What are the typical timelines?

Topical steroid exclusivity timelines in the US generally follow:

Market exclusivity (if applicable) tied to new clinical investigations
Patent term for listed patents in Orange Book (or equivalent national listings)
Regulatory exclusivities outside the US (data and market exclusivity rules vary by jurisdiction)

Typical pattern by product age

Older molecules (hydrocortisone, triamcinolone, betamethasone esters): most composition patents are likely out of term; remaining patents focus on formulation and process.
Later reformulations (new vehicle, new strength, improved spray/gel): formulation/process patents can extend protection meaningfully into the next decade depending on filing date.

Practical consequence: generic risk is highest where only formulation/process patents remain and where courts or settlements allow “at-risk” entry with design-around formulations.

What is the Orange Book status of plain topical corticosteroids?

Orange Book status drives US generic strategy:

Whether patents are listed for the exact NDA/ANDA + strength + dosage form
Whether those patents are use, method, or formulation categories
Whether listed patents have already expired

Commercial impact: Paragraph IV filings require a clear contested listed patent. If a brand only lists weak/late-expiring formulation patents, generic filers often win settlement economics with earlier entry.

Which companies are challenging D07A brands with Paragraph IV filings or generic launches?

In D07A, challenger patterns are consistent:

Multiple generic players target the most widely prescribed mid/high potency presentations where demand density supports launch costs.
Companies with “topical formulation capability” are more likely to file because design-around is real for vehicle and particle engineering.
Indian and global generic firms often drive the first wave for APIs that are no longer under strong composition protection.

Business implication: the highest probability of meaningful litigation happens when the brand has multiple listed patents for the exact formulation that the generic must avoid to launch without risk.

How strong is the patent estate for D07A plain corticosteroids?

Strength is a function of:

number of listed patents for the exact marketed presentation
breadth of each claim set across potential design-arounds
how consistently courts treat vehicle/formulation claims in the relevant jurisdiction
whether patents survive validity challenges and the litigation record

Key indicators of strong estates

Multiple active patents all mapping to the marketed strength and dosage form
Formulation patents with objective properties that are difficult to replicate (viscosity windows, particle size bands, crystallinity requirements)
Process patents that prevent straightforward manufacturing substitution without infringement

Key indicators of weaker estates

Narrow claims tied to one excipient or one step in a process that can be replaced
Patents that read only on a specific salt/ester or an intermediate
Method-of-use patents that do not translate into manufacturing blocking power in settlements

What generic entry risks exist for plain topical corticosteroids?

Generic risk assessment should be presentation-specific:

Are there active formulation/process patents in Orange Book (US) or national equivalents?
Do the listed patents cover the exact concentration and vehicle?
Is there a plausible design-around that keeps bio-performance while avoiding infringement?
Is there a settlement pattern that has already “opened the door” for competitors?

Common generic launch scenarios

Early settlement: brand agrees to a delayed launch date with narrow “carve-outs” to avoid later exclusivity disputes.
At-risk launch: generic launches before some patents expire, betting on non-infringement or invalidity.
Design-around switch: generic changes vehicle system or particle parameters, aiming to avoid formulation/polymorph/process claims.

How does ATC D07A compare across molecules in terms of patent cliffs and competitive pressure?

Within D07A, patent cliff timing differs by molecule and reformulation cadence:

Betamethasone esters: vehicle/formulation and strength-specific patents frequently matter.
Mometasone: often sees multiple reformulations and strength-specific IP layers.
Clobetasol derivatives: high potency creates willingness to pay, supporting more sustained lifecycle management.
Triamcinolone and desonide: breadth of generics historically compresses remaining value; however, specific vehicles and pediatric/regimen claims can still produce pockets of exclusivity.
Hydrocortisone: broad OTC and generic availability compresses patent value; formulation/device patents can still occur but are typically less likely to sustain large estates.

What formulation patents are most common for topical corticosteroids?

The most litigated or commercially decisive claim themes for plain topical steroids include:

Vehicle composition: cream base recipes, ointment structured gels, lotion solvent blends.
Penetration enhancement strategy: surfactants, fatty alcohols, and solubilizers that change skin uptake.
Rheology control: thickener selection and concentration to achieve spreadability and stay-on.
Particle size/crystal form: engineered properties for consistent dose delivery.

Why these matter for design-arounds

Generic filers cannot simply “use the same API at the same strength.” They need a vehicle that meets bio-performance targets while avoiding infringement of formulation/process patents tied to objective parameters.

What method-of-use patents matter for D07A and how do they affect generic approval?

Method-of-use patents can affect launch timing via:

settlement leverage in litigation even when manufacturing design-arounds are feasible
labeling carve-outs that reflect settlement terms
enforcement strategies that target prescribers or distribution channels, depending on jurisdiction and claim types

For generics, the practical impact is often indirect:

the generic may need to negotiate labeling or pricing launch timing to avoid post-launch disputes.

What patent litigation affects plain topical corticosteroid products?

D07A litigation typically clusters around:

infringement of formulation/process patents for the marketed vehicle/strength
validity arguments tied to obviousness, lack of written description, or inadequate enablement
claim construction debates focusing on specific excipient systems, particle size ranges, or manufacturing steps

Settlement patterns

Common outcomes include:

delayed generic launch for a date range covering remaining patents
licensing rights for later filings
non-admission clauses and confidentiality, with public signal limited to dismissal orders and entry date announcements

Which deals and licensing agreements shape the D07A landscape?

Licensing in topical steroids often aims to:

allow authorized generics with negotiated dates
permit specific design-arounds while preserving brand protection for remaining strengths
resolve multi-jurisdiction disputes through global settlement terms

Because settlements are presentation-specific, downstream commercial results often show:

launch by strength
slower erosion where vehicle patents remain active
faster erosion where only weak formulation claims survive

Regulatory status: how do FDA pathways influence patent strategy for topical steroids?

For US products, generic applicants choose an ANDA route when feasible. Patent strategy typically centers on:

Orange Book listed patents for the NDA product
Paragraph IV decisions to challenge listed patents at filing
carve-outs and design-around formulations to avoid infringement

If a brand product is tied to a formulation that is hard to replicate, the ANDA filer’s risk rises, increasing the likelihood of settlement-driven timelines.

How do regional exclusivity rules outside the US change the outlook for D07A?

Patent and exclusivity frameworks vary by jurisdiction:

EU rules include data exclusivity and market exclusivity concepts under different legal standards than the US.
National patent term adjustments and supplementary protection certificates (SPCs) can extend protection for certain pharmaceutical categories.
Litigation and enforcement forums drive settlement economics.

Commercial consequence: a generic may be ready in the US but face slower entry in countries with active formulation/patent coverage and stricter enforcement.

Key product-by-product patent landscape: what is protected and what drives launch timing?

A complete, accurate product-by-product table requires current, presentation-level Orange Book and national listing data plus active litigation records. Under the constraints of this request, no such dataset is provided here, so a fully enumerated landscape by brand, strength, and patent number cannot be produced without risking incorrect facts.

Key takeaways

D07A plain corticosteroids are dominated by vehicle/formulation and process IP once composition-of-matter protection falls away.
Generic entry risk is presentation-specific and hinges on whether active patents are listed for the exact dosage form and strength on the label.
Strongest estates align with objective formulation/process parameters that are difficult to replicate, raising settlement likelihood and delaying launches.
Weakest estates tie to narrow design features that generics can substitute without losing therapeutic performance.
The US and non-US outlook will differ because listed patents and exclusivity regimes differ across jurisdictions.

FAQs

1) Which D07A topical steroids have the highest likelihood of generic settlement delays?

2) What formulation attributes are most important in patent enforcement for topical corticosteroids?

3) How do particle size and polymorph patents affect topical steroid generics?

4) What is the typical structure of settlement agreements in US topical steroid patent disputes?

5) How does dosage strength influence the patent landscape for the same topical steroid API?

References

(No sources cited because the request does not include product- and jurisdiction-specific patent listing or litigation datasets required for accurate citation.)

Drugs in ATC Class D07A

Subclasses in ATC: D07A - CORTICOSTEROIDS, PLAIN

ATC Class D07A (Plain Corticosteroids) Market Dynamics and Patent Landscape: What Protects Top Dermatology Steroids, When Do Patents Expire, and Where Generic Risk Is Highest